Robert Huddart is Professor of Urological Cancer at the Institute of Cancer Research, and is an Honorary Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust.
He is an internationally recognised specialist who manages and treats patients with urological cancer - cancer that affects the bladder, prostate, kidney and testicles. He is an honorary consultant at Croydon University Hospital and runs clinics at Cancer Clinic London, Parkside, Wimbledon and Shirley Oaks Hospital, Croydon.
Education and training
Professor Robert Huddart studied medicine at St Peter’s College, Oxford and at the University College/Middlesex Hospital, London before undertaking further general medical training in London, Oxford and Cambridge. He moved to The Royal Marsden in 1989 for specialist training in Clinical Oncology.
He completed a PhD in the molecular biology of testicular cancer before completing his training at The Royal Marsden. He was appointed as Senior Lecturer and Honorary Consultant at the Institute of Cancer Research and Royal Marsden Hospital in 1996 being promoted to Reader in 2007 and Professor in 2015.
Professor Huddart has developed an international reputation in management of urological cancer with a particular focus on bladder and testicular cancer regularly speaking at major international meetings on these topics.
He has extensive experience in all forms of drug (including chemotherapy and immunotherapy) of urological cancer. He is also practiced in advanced radiotherapy techniques of urological cancer.
He leads the UK's largest testicular cancer network in the South East of England he has been involved in writing the National Institute of Health and Care Excellence (NICE) guidelines in the management of bladder cancer.
Professor Huddart is a highly experienced clinical researcher. He has published over 230 peer reviewed papers including publications in high profile journals such a New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and European Urology. He has an h index of 59 (March 2020) [a measure of impact of research work].
He has a led a number of major practice changing UK trials including BC2001, MRC TE23, 111 study, HYBRID and RAIDER
He is former chair of national testis research group and member of the bladder cancer study group. He is current CT RAD work stream chair and works on the NCRI bladder cancer localised and advanced study groups.
Professor Huddart offers a wide range of radiotherapy treatments for the spectrum of urological cancer including Prostate, Bladder and Testicular cancer. He and his team pioneered Intensity modulated radiotherapy, image guided and adaptive radiotherapy.
He is particularly a leading exponent of bladder preserving chemo-radiotherapy for bladder cancer and pioneered ‘plan of the day’ adaptive radiotherapyHe is currently studying Magnetic Resonance guided radiotherapy (at the Royal Marsden Hospital) based on the Elekta Unity MR Linac.
These techniques in addition to stereotactic radiotherapy are offered at either the Royal Marsden or Cancer Centre London.
- Prostate cancer: Intensity modulated radiotherapy, image guided radiotherapy, MR guided radiotherpy (MR Linac), Stereotactic radiotherapy for localised and oligometastatic disease.
- Bladder cancer: Chemo-Radiotherapy, Intensity modulated radiotherapy, Adaptive ‘paln of the day’ radiotherapy, MR guided radiotherapy
- Testicular cancer: Intensity modulated radiotherapy for advanced NSGCT and stage 2 seminoma.
Professor Huddart is experienced in wide spectrum of drug therapy for urological cancer. In testicular cancer he has lead trials in adjuvant chemotherapy for Non Seminoma and for advanced Non-seminoma.
In bladder cancer he had been involved in the multiple clinical trials in the neoadjuvant, first and second line advanced cancer centre including in the development of immunotherapy and targeted therapies.
He also offers a comprehensive service of prostate drug therapy including adjuvant therapy for advanced disease in the hormone sensitive phase, non-metastatic castrate sensitive disease and isotope therapy.
- Testicular cancer: BEP, Carboplatin and Salvage chemotherapy
- Prostate cancer: Full range of systemic therapies including Docetaxol, Carbazitazel, LHRH agonist, Abiraterone, Enzalutamide and Apalatumide
- Bladder cancer: Chemotherapy and immunotherapy including Cisplatin/Gemcitabine, Pembroluzimab, Atezoluzimab and Vinflunine
Radioactive isotopes are one of the newest treatments for advanced prostate cancer. Professor Huddart can offer both Radium 223 and Lutetium PSMA at Cancer Centre London
- Professor Huddart can offer second opinions
- Remote Video Consultations can be arranged by prior discussion
- Insured patients should note that second opinions are not normally funded by insurance companies